Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Salivary SARS-CoV-2 antigen rapid detection: a prospective cohort study

Daniela Basso, Ada Aita, View ORCID ProfileAndrea Padoan, Chiara Cosma, Filippo Navaglia, Stefania Moz, Nicole Contran, Carlo-Federico Zambon, Anna Maria Cattelan, View ORCID ProfileMario Plebani
doi: https://doi.org/10.1101/2020.12.24.20248825
Daniela Basso
1Department of Medicine – DIMED, Laboratory Medicine, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: daniela.basso@unipd.it
Ada Aita
1Department of Medicine – DIMED, Laboratory Medicine, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Padoan
1Department of Medicine – DIMED, Laboratory Medicine, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrea Padoan
Chiara Cosma
1Department of Medicine – DIMED, Laboratory Medicine, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filippo Navaglia
1Department of Medicine – DIMED, Laboratory Medicine, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefania Moz
1Department of Medicine – DIMED, Laboratory Medicine, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Contran
1Department of Medicine – DIMED, Laboratory Medicine, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlo-Federico Zambon
1Department of Medicine – DIMED, Laboratory Medicine, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Maria Cattelan
2Tropical and Infectious Diseases Unit, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Plebani
1Department of Medicine – DIMED, Laboratory Medicine, University Hospital of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mario Plebani
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background SARS-CoV-2 quick testing and reporting are now considered relevant for the containment of new pandemic waves. Antigen testing in self-collected saliva might be useful. We compared the diagnostic performance of salivary and naso-pharyngeal swab (NPS) SARS-CoV-2 antigen detection by a rapid chemiluminescent assay (CLEIA) and two different point-of-care (POC) immunochromatographic assays, with that of molecular testing.

Methods 234 patients were prospectively enrolled. Paired self-collected saliva (Salivette) and NPS were obtained to perform rRT-PCR, chemiluminescent (Lumipulse G) and POC (NPS: Fujirebio and Abbott; saliva: Fujirebio) for SARS-CoV-2 antigen detection.

Results The overall agreement between NPS and saliva rRT-PCR was 78.7%, reaching 91.7% at the first week from symptoms onset. SARS-CoV-2 CLEIA antigen was highly accurate in distinguishing between positive and negative NPS (ROC-AUC=0.939, 95%CI:0.903-0.977), with 81.6% sensitivity and 93.8% specificity. This assay on saliva had an overall good accuracy (ROC-AUC=0.805, 95%CI:0.740-0.870), reaching the optimal value within 7 days from symptom onset (Sensitivity: 72%; Specificity: 97%). POC antigen in saliva had a very limited sensitivity (13%), performing better in NPS (Sensitivity: 48% and 66%; Specificity: 100% and 99% for Espline and Abbott respectively), depending on viral loads.

Conclusions Self-collected saliva is a valid alternative to NPS for SARS-CoV-2 detection not only by molecular, but also by CLEIA antigen testing, for which the highest diagnostic accuracy was achieved in the first week from symptom onset. Saliva is not suitable for POC, although the accuracy of these tests appears satisfactory for NPS with high viral load.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No fundings

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Local Ethic Committee Nr. 27444, University-Hospital of Padova, Italy

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will be make available upon request

  • List of abbreviations

    (NPS)
    naso-pharyngeal swab
    (CLEIA)
    chemiluminescent assay
    (POC)
    point-of-care
    (ROC)
    receiver operating characteristic
    (AUC)
    area under the receiver operating characteristic curve
    (SD)
    standard deviation.
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted December 27, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Salivary SARS-CoV-2 antigen rapid detection: a prospective cohort study
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Salivary SARS-CoV-2 antigen rapid detection: a prospective cohort study
    Daniela Basso, Ada Aita, Andrea Padoan, Chiara Cosma, Filippo Navaglia, Stefania Moz, Nicole Contran, Carlo-Federico Zambon, Anna Maria Cattelan, Mario Plebani
    medRxiv 2020.12.24.20248825; doi: https://doi.org/10.1101/2020.12.24.20248825
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Salivary SARS-CoV-2 antigen rapid detection: a prospective cohort study
    Daniela Basso, Ada Aita, Andrea Padoan, Chiara Cosma, Filippo Navaglia, Stefania Moz, Nicole Contran, Carlo-Federico Zambon, Anna Maria Cattelan, Mario Plebani
    medRxiv 2020.12.24.20248825; doi: https://doi.org/10.1101/2020.12.24.20248825

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (269)
    • Allergy and Immunology (549)
    • Anesthesia (134)
    • Cardiovascular Medicine (1747)
    • Dentistry and Oral Medicine (238)
    • Dermatology (172)
    • Emergency Medicine (310)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
    • Epidemiology (10779)
    • Forensic Medicine (8)
    • Gastroenterology (583)
    • Genetic and Genomic Medicine (2933)
    • Geriatric Medicine (286)
    • Health Economics (531)
    • Health Informatics (1918)
    • Health Policy (833)
    • Health Systems and Quality Improvement (743)
    • Hematology (290)
    • HIV/AIDS (627)
    • Infectious Diseases (except HIV/AIDS) (12496)
    • Intensive Care and Critical Care Medicine (684)
    • Medical Education (299)
    • Medical Ethics (86)
    • Nephrology (321)
    • Neurology (2780)
    • Nursing (150)
    • Nutrition (431)
    • Obstetrics and Gynecology (553)
    • Occupational and Environmental Health (597)
    • Oncology (1454)
    • Ophthalmology (440)
    • Orthopedics (172)
    • Otolaryngology (255)
    • Pain Medicine (190)
    • Palliative Medicine (56)
    • Pathology (379)
    • Pediatrics (864)
    • Pharmacology and Therapeutics (362)
    • Primary Care Research (333)
    • Psychiatry and Clinical Psychology (2630)
    • Public and Global Health (5338)
    • Radiology and Imaging (1002)
    • Rehabilitation Medicine and Physical Therapy (594)
    • Respiratory Medicine (722)
    • Rheumatology (329)
    • Sexual and Reproductive Health (288)
    • Sports Medicine (278)
    • Surgery (327)
    • Toxicology (47)
    • Transplantation (149)
    • Urology (125)